FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies

FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies

Federal regulators declined to approve a nasal spray to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen. The U.S. Food and Drug Administration told ARS Pharmaceuticals Inc., of San Diego, that the company needs to conduct another study on repeat doses of epinephrine, a drug that halts potentially life-threating reactions, called an…

FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies

Federal regulators declined to approve a nasal spray to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen. The U.S.

FDA says more research needed before approval for nasal spray to treat dangerous allergies

The agency says the pharmaceutical company needs to conduct another study on repeat doses of epinephrine using the device compared with injections.

FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies

Federal regulators declined to approve a nasal spray to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen. The U.S.

FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies

Federal regulators declined to approve a nasal spray to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen. The U.S.

FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies

Federal regulators declined to approve a nasal spray to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen. The U.S. Food and Drug Administration told ARS Pharmaceuticals Inc., of San Diego, that the company needs to conduct another study on repeat doses of epinephrine, a drug that halts potentially life-threating reactions, called a…